![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sinopharm’s Wuhan Affiliate to Produce 1 Billion COVID-19 Shots a Year
Sinopharm’s Wuhan Affiliate to Produce 1 Billion COVID-19 Shots a Year
![Sinopharm_Logo.png](https://www.fdanews.com/ext/resources/test/Drug-Images4/Sinopharm_Logo.png?t=1597974966&width=430)
The Wuhan Institute of Biological Products, an affiliate of Chinese drugmaker Sinopharm, has announced that it will expand its annual capacity to manufacture at least 1 billion COVID-19 vaccine doses.
Sinopharm has set a total annual capacity target of 3 billion COVID-19 vaccine doses. Another Sinopharm affiliate, the Beijing Institute of Biological Products, already has an annual capacity of 1 billion doses and is also building a new facility to increase production.
In early May, the World Health Organization listed one of Sinopharm’s COVID-19 vaccines for emergency use, clearing the way for its global distribution through the Covax initiative, which is aimed at equitable access to COVID-19 vaccines.
Upcoming Events
-
18Jul
-
21Oct